Shilpa Medicare Names Pharma Veteran Vellaian Karuppiah as COO, Formulations
New Delhi: Shilpa Medicare Limited has appointed Dr Vellaian Karuppiah as Chief Operating Officer (COO), Formulations with effect from April 23, 2026, as part of its senior management strengthening strategy, with the appointment approved by the company's Nomination and Remuneration Committee.
Dr Karuppiah joins as a senior managerial personnel in a full-time role and brings over 33 years of extensive experience across the pharmaceutical value chain, covering formulation and analytical R&D, regulatory affairs, manufacturing science and technology, technology transfer, engineering and projects, quality systems, EHS/ESG, supply chain management, production planning, and end-to-end manufacturing operations.
He has held leadership and C-suite roles in several globally recognised pharmaceutical companies, including Gland Pharma (Fosun Group), Strides Group, Dr Reddy’s Laboratories, Actavis (now part of Teva), and Orchid Healthcare (associated with Hospira/Pfizer), reflecting significant global exposure and cross-functional expertise.
In his recent assignments as Chief Operating Officer at Acme Group and Immacule Lifesciences, he played a key role in enhancing manufacturing efficiency, strengthening supply chain resilience, improving quality systems, and integrating R&D operations, thereby contributing to overall business growth and competitiveness.
Dr Karuppiah holds a postgraduate degree and a doctorate in Pharmacy, along with executive management qualifications from leading institutions in India and abroad.The company stated that his appointment is expected to significantly strengthen its formulation business, drive operational excellence, and support long-term sustainable growth through improved efficiencies and strategic leadership.
